Novel Heart Failure Technology from Alleviant Medical Gains FDA Approval for New Pivotal Trial and Breakthrough Designation for Significant Patient Population - 1/7/2025
Diabetes Treatment: A Story of Complicated Progress and Great Potential
RiverVest Managing Director Derek Rapp discusses the global health threat of diabetes and shares his thoughts on the innovation ecosystem that is essential to achieving better outcomes for patients.
ST. LOUIS–(December 12, 2024)— RiverVest Venture Partners, a leading life science venture capital firm, today announced that John C. Cambier, Ph.D., and Gary De Crescenzo have joined the firm’s Scientific Advisory Board. Composed of leaders in medical research, RiverVest’s Scientific Advisory Board provides expert guidance to the firm as it identifies and invests in promising biopharmaceutical and medical device companies.
RiverVest speaks with Lyn Baranowski, CEO of portfolio company Avalyn Pharma, about who she is, what brought her to Avalyn, and what fuels her passion for building great companies.
RiverVest strives to improve the lives of patients, support entrepreneurs, and earn the trust of investors through science, strategy, and innovation.Contact us at info@rivervest.com
Transparency in Coverage Rule: To access the machine-readable files created and published by United Healthcare, please click here.